Search

Displaying results 91 - 100 of 864 in total
  1. Drug

    Calcium carbonate

    go.drugbank.com/drugs/DB06724
    ApprovedInvestigational

    Calcium carbonate is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ...

    Mixtures: Se-Natal One, Virt-Care OneProducts: Care One Calcium Antacid
  2. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    Deutivacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibr...

  3. Target

    F-box/WD repeat-containing protein 1A

    go.drugbank.com/bio_entities/BE0021224
    TargetHumans

    Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins (PubMed:10066435, PubMed:10497169, PubMed:...

    Polypeptides: F-box/WD repeat-containing protein 1A
  4. Drug

    Imlunestrant

    go.drugbank.com/drugs/DB19043
    ApprovedInvestigational

    on September 25, 2025 [L54051] as a treatment for estrogen receptor (ER)-positive, HER2-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer with progression on at least one

  5. Drug

    Lactulose

    go.drugbank.com/drugs/DB00581
    ApprovedInvestigational

    received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health Organization's List of Essential Medicines as one … considered after lifestyle and dietary modifications fail and the fact that lactulose therapy cannot be ethically withheld from patients diagnosed with PSE in a placebo study, the substance may just be one

  6. Drug

    Zanubrutinib

    go.drugbank.com/drugs/DB15035
    ApprovedInvestigational

    Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. … [L39367] In September 2021, zanubrutinib was granted another accelerated approval for the treatment of relapsed or refractory marginal zone lymphoma who have received at least one anti-CD20-based regimen

  7. Drug

    Acalabrutinib

    go.drugbank.com/drugs/DB11703
    ApprovedInvestigational

    kinase (BTK) inhibitor indicated for the treatment of chronic lymphocytic leukemia, small lymphocytic lymphoma, and in adult patients with Mantle cell lymphoma (MCL) who have already received at least one

  8. Drug

    Vanzacaftor

    go.drugbank.com/drugs/DB18373
    ApprovedInvestigational

    Vanzacaftor is a small molecule cystic fibrosis transmembrane conductance regulator (CFTR) corrector. It is used alongside other CFTR correctors and CFTR potentiators to increase the quantity and function of CFTR at the cell surface in p...

  9. Drug

    Mogamulizumab

    go.drugbank.com/drugs/DB12498
    ApprovedInvestigational

    approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one

  10. Drug

    Vitamin E

    go.drugbank.com/drugs/DB00163
    ApprovedInvestigationalNutraceuticalVet approved

    In 1922, vitamin E was demonstrated to be an essential nutrient . Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active . Vitamin E acts as an antio...

    Mixtures: Folet One, Swiss One